MediVas Announces Signing of Collaboration Agreement with Pfizer

Announced the signing of a collaborative research agreement with Pfizer. The agreement is focused on the research and development of advanced delivery methods for proprietary Pfizer compounds to treat diseases of the eye.

SAN DIEGO, CA, USA | Jan 24, 2007 |
MediVas, LLC, developer of novel drug delivery platforms, today announced the signing of a collaborative research agreement with Pfizer. The agreement is focused on the research and development of advanced delivery methods for proprietary Pfizer compounds to treat diseases of the eye. By combining the fully biodegradable and biocompatible MediVas polymers with the Pfizer compounds, MediVas and Pfizer hope to create a product that can change the paradigm of how ophthalmic treatments are administered. Financial terms of the agreement were not disclosed.

Commenting on the announcement, Kenneth W. Carpenter, MediVas’ President and CEO said, “We are excited to enter this relationship with Pfizer and we are confident that by combining Pfizer’s compounds with our best in class polymer delivery system we can help to increase patient compliance and significantly improve treatment of diseases of the eye. We look forward to moving this collaboration ahead quickly and to entering into a broader relationship with Pfizer.”

About MediVas: Using its proprietary family of biodegradable and biocompatible polymers, MediVas has developed unique platforms for the delivery of biologics. MediVas is utilizing its novel polymer technology in collaboration with some of the world's largest pharmaceutical companies, as well as on its own internal product development efforts, to create groundbreaking medical advancements. The more than $50 billion biologics market is the next frontier in medicine and MediVas is uniquely poised to take advantage of this growing space. By combining therapeutic proteins and other biologics with a MediVas polymer, delivery routes that were previously unattainable, such as oral, intranasal, inhaled or subcutaneous injection, can now be achieved. By opening up these delivery routes, MediVas’ delivery system can make the administration of the biologic more convenient, more efficacious and safer, leading to higher patient compliance and overall better health.

SOURCE: MediVas, LLC

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top